ITGAM and neoplasm: (20) found that in an in vivo experiment, XYS-treated mice had fewer liver metastases and a lower liver weight, and XYS could significantly decrease the CD11b+F4/80+ macrophage population in the primary tumor tissue, accompanied by a significant reduction in CD11b+GrloLy6Chi cells.